Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891460084> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2891460084 endingPage "7564" @default.
- W2891460084 startingPage "7564" @default.
- W2891460084 abstract "7564 Background: Efficacy of L-asparaginase-based regimens has been confirmed for patients with extranodal natural killer/T-cell lymphoma (ENKTL). However, targeted therapy and optimal chemotherapy regimens for ENKTL remain to be determined. As high levels of vascular endothelial growth factor A (VEGF) is associated with a poor prognosis in ENKTL, we evaluated the efficacy and safety for bevacizumab (BEV) in the combination with gemcitabine, PEG-asparaginase, oxaliplatin and dexamethasone (BEV-GemAOD) regimen in untreated ENKTL in the Phase II Study (NCT 01921790). Methods: Patients with newly diagnosed ENKTL in stageⅠ-Ⅳ from 18 to 80 years were eligible for enrollment. BEV-GemAOD regimen (bevacizumab 7.5 mg/kg d1; gemcitabine 1000 mg/m2 d1, d8; PEG-aspargase 2500 U/m2 d1; oxaliplatin 130 mg/ m2 d1; dexamethasone 20 mg, d1-3; q3w) was planned as the protocol treatment. Patients with stage I/II received sandwich chemoradiation (BEV-GemAOD×3 cycles followed by RT 50.4 Gy followed by BEV-GemAOD×3 cycles). For stage III/IV, BEV-GemAOD regimen was repeated for six cycles. The primary endpoint was overall response rate (ORR) after six cycles of BEV-GemAOD. Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Results: 56 patients were enrolled from Oct 2013 to Feb 2018. 43 patients were evaluable for response: the median age, 37 years (range: 18-65 years); female, 25.6%; ECOG PS > 1, 20.9%; stageⅣ, 37.2%; elevated LDH, 39.5%; elevated EBV DNA, 60.5%. After 2 cycles of BEV-GemAOD, ORR were 100%. CR rate (CRR) in stage Ⅰ/Ⅱ and Ⅲ/Ⅳ were 88.9% (24/27) and 25% (4/16), respectively. After 6 cycles ORR were still 100%. CRR increased to 100% (27/27) and 87.5% (14/16), respectively. At median follow-up of 25.3 months, 2-year PFS and OS were 83.3% and 78.8%. The most common hematologic adverse event of grade 3/4 was neutropenia (32.6%). No patient died of treatment related toxicity. Conclusions: These results demonstrate that BEV-GemAOD regimen is feasible and provides high ORR, CRR and survival for either early- or late-stage patients with newly diagnosed ENKTL. Clinical trial information: NCT01921790." @default.
- W2891460084 created "2018-09-27" @default.
- W2891460084 creator A5004906797 @default.
- W2891460084 creator A5005765923 @default.
- W2891460084 creator A5015287299 @default.
- W2891460084 creator A5023320780 @default.
- W2891460084 creator A5024115437 @default.
- W2891460084 creator A5031344912 @default.
- W2891460084 creator A5038871279 @default.
- W2891460084 creator A5039416429 @default.
- W2891460084 creator A5042092772 @default.
- W2891460084 creator A5045587556 @default.
- W2891460084 creator A5046049972 @default.
- W2891460084 creator A5061006889 @default.
- W2891460084 creator A5061873068 @default.
- W2891460084 creator A5087356851 @default.
- W2891460084 date "2018-05-20" @default.
- W2891460084 modified "2023-10-16" @default.
- W2891460084 title "A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma." @default.
- W2891460084 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.7564" @default.
- W2891460084 hasPublicationYear "2018" @default.
- W2891460084 type Work @default.
- W2891460084 sameAs 2891460084 @default.
- W2891460084 citedByCount "2" @default.
- W2891460084 countsByYear W28914600842023 @default.
- W2891460084 crossrefType "journal-article" @default.
- W2891460084 hasAuthorship W2891460084A5004906797 @default.
- W2891460084 hasAuthorship W2891460084A5005765923 @default.
- W2891460084 hasAuthorship W2891460084A5015287299 @default.
- W2891460084 hasAuthorship W2891460084A5023320780 @default.
- W2891460084 hasAuthorship W2891460084A5024115437 @default.
- W2891460084 hasAuthorship W2891460084A5031344912 @default.
- W2891460084 hasAuthorship W2891460084A5038871279 @default.
- W2891460084 hasAuthorship W2891460084A5039416429 @default.
- W2891460084 hasAuthorship W2891460084A5042092772 @default.
- W2891460084 hasAuthorship W2891460084A5045587556 @default.
- W2891460084 hasAuthorship W2891460084A5046049972 @default.
- W2891460084 hasAuthorship W2891460084A5061006889 @default.
- W2891460084 hasAuthorship W2891460084A5061873068 @default.
- W2891460084 hasAuthorship W2891460084A5087356851 @default.
- W2891460084 hasConcept C121608353 @default.
- W2891460084 hasConcept C126322002 @default.
- W2891460084 hasConcept C141071460 @default.
- W2891460084 hasConcept C143998085 @default.
- W2891460084 hasConcept C203092338 @default.
- W2891460084 hasConcept C2776694085 @default.
- W2891460084 hasConcept C2777063308 @default.
- W2891460084 hasConcept C2777802072 @default.
- W2891460084 hasConcept C2778336483 @default.
- W2891460084 hasConcept C2780258809 @default.
- W2891460084 hasConcept C2780962732 @default.
- W2891460084 hasConcept C2781413609 @default.
- W2891460084 hasConcept C31760486 @default.
- W2891460084 hasConcept C526805850 @default.
- W2891460084 hasConcept C535046627 @default.
- W2891460084 hasConcept C71924100 @default.
- W2891460084 hasConcept C90924648 @default.
- W2891460084 hasConceptScore W2891460084C121608353 @default.
- W2891460084 hasConceptScore W2891460084C126322002 @default.
- W2891460084 hasConceptScore W2891460084C141071460 @default.
- W2891460084 hasConceptScore W2891460084C143998085 @default.
- W2891460084 hasConceptScore W2891460084C203092338 @default.
- W2891460084 hasConceptScore W2891460084C2776694085 @default.
- W2891460084 hasConceptScore W2891460084C2777063308 @default.
- W2891460084 hasConceptScore W2891460084C2777802072 @default.
- W2891460084 hasConceptScore W2891460084C2778336483 @default.
- W2891460084 hasConceptScore W2891460084C2780258809 @default.
- W2891460084 hasConceptScore W2891460084C2780962732 @default.
- W2891460084 hasConceptScore W2891460084C2781413609 @default.
- W2891460084 hasConceptScore W2891460084C31760486 @default.
- W2891460084 hasConceptScore W2891460084C526805850 @default.
- W2891460084 hasConceptScore W2891460084C535046627 @default.
- W2891460084 hasConceptScore W2891460084C71924100 @default.
- W2891460084 hasConceptScore W2891460084C90924648 @default.
- W2891460084 hasIssue "15_suppl" @default.
- W2891460084 hasLocation W28914600841 @default.
- W2891460084 hasOpenAccess W2891460084 @default.
- W2891460084 hasPrimaryLocation W28914600841 @default.
- W2891460084 hasRelatedWork W1480235848 @default.
- W2891460084 hasRelatedWork W2008532487 @default.
- W2891460084 hasRelatedWork W2039328218 @default.
- W2891460084 hasRelatedWork W2040941344 @default.
- W2891460084 hasRelatedWork W2303669053 @default.
- W2891460084 hasRelatedWork W2534645004 @default.
- W2891460084 hasRelatedWork W2589765552 @default.
- W2891460084 hasRelatedWork W2604148568 @default.
- W2891460084 hasRelatedWork W2999904863 @default.
- W2891460084 hasRelatedWork W3043075404 @default.
- W2891460084 hasVolume "36" @default.
- W2891460084 isParatext "false" @default.
- W2891460084 isRetracted "false" @default.
- W2891460084 magId "2891460084" @default.
- W2891460084 workType "article" @default.